Bosentan for digital ulcers in patients with systemic sclerosis

Journal of Dermatology

Volumn 39, Issue 1, 2012, Pages 48-51

  Nagai, Yayoi ^a   Hasegawa, Michiko ^a   Hattori, Tomoyasu ^a   Okada, Etsuko ^a   Tago, Osamu ^a   Ishikawa, Osamu ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

bosentan; digital pain; digital ulcer; liver dysfunction; systemic sclerosis.

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BOSENTAN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIGITAL ULCER; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; RAYNAUD PHENOMENON; RECURRENT DISEASE; SIDE EFFECT; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; ULCER; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HAND DERMATOSES; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855344464     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01299.x     Document Type: Article

References (14)

1. Dhillon S,. Bosentan A review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs 2009; 69: 2005-2024.
2. White B, Bauer EA, Goldsmith LA, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology committee on design and outcomes in clinical traials in systemic sclerosis. Arthritis Rheum 1995; 38: 351-360.
3. Leroy EC, Black C, Fleischmaior R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205. (Pubitemid 18073738)
4. Nagai Y, Igarashi N, Ishikawa O,. Generalized morphea-like systemic sclerosis; a subtype of diffuse cutaneous systemic sclerosis presenting with unusual cutaneous features. Eur J Dermatol 2008; 18: 715-716.
5. Hettemo ME, Zhang D, Bootsma H, kallenberg CGM,. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007; 66: 1398-1399. (Pubitemid 47492490)
6. Selenko-Gebauner N, Duschek N, Minimair G, Stingl G, Karlhofer F,. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatol 2006; 43: iii45-iii48. (Pubitemid 44446779)
7. Seibold JR, Matucci-Cerinie M, Denton CP, et al. Bosentan reduces the number of new digital ulcses in patients with systemic sclerosis. Ann Rheum Dis 2006; 65 (Suppl II): 90.
8. Black C, Denton CP, Frst DE, et al. Bosentan reduces the number of new digital ilcers in patients with systemic sclerosis: open label extension to a double-blind trial. Ann Rheum Dis 2006; 65 (Suppl II): 384.
9. Korn JH, Mayes M, Matucci CM, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rhuem 2004; 50: 3985-3993. (Pubitemid 39643947)
10. Tsifetaki N, Botzoris V, Alamanos Y, Argyriou E, Zioga A, Drosos AA,. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. J Rheumatol 2009; 37: 1550-1552.
11. Gedcfa de la Pena-Lefebvre P, Rodriguez RS, Valero Exposito M, et al. Long -term experience of bosentan for treating ulcers and healed ulcers in systemic patients. Rheumatolgy 2008; 47: 464-466.
12. Nagai Y, Mihara S, Okada E, Sato K, Ohi S, Ishikawa O,. Severe liver dysfunction due to bosentan in a patient with mixed connective tissue disease. Eur J Dermatol 2008; 18: 190-191. (Pubitemid 351554812)
13. Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatol 2010; 49: 1374-1382.
14. Hasegawa M, Nagai Y, Tamura A, Ishikawa O,. Arteriographic evaluation of vascular changese of the extremities in patients with systemic sclerosis. Br J Dermatol 2006; 155: 1159-1164. (Pubitemid 44729989)